ArticleMolecular biology reports2025
Comparison of the neuroprotective effects of gossypin on cisplatin-induced neurotoxicity in vitro and in vivo.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Investigation of the Efficacy of Orientin in Streptozotocin-Induced Type 1 Diabetes Model and Pancreatic Beta-TC6 Cells.Journal of biochemical and molecular toxicology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCisplatin (CIS), a widely used chemotherapeutic agent, is known for its severe neurotoxic side effects. This study investigates the neuroprotective effects of gossypin (GOS), a bioflavonoid with antioxidant and anti-inflammatory properties, against CIS-induced neurotoxicity. METHODS AND
resultsIn-vitro and in-vivo experiments were conducted.50 male Mus Musculus mice were divided into five groups (n:10). Gossypin was administered at varying doses to (in-vitro: 50, 75, 100 µM; in vivo: 5, 10, 20 mg/kg/day) evaluate its protective effects. Results showed gossypin significantly improved cell viability dose-dependently, normalized oxidative stress markers Superoxide dismutase (SOD) activity and glutathione (GSH) and malondialdehyde (MDA) levels, reduced pro-apoptotic and inflammatory genes (CASP-3, CASP-9, TNF-α, NF-kB, iNOS), and increased anti-apoptotic markers (BCL2/BAX ratio, nNOS). Histopathological analysis revealed gossypin mitigated CIS-induced brain tissue damage.
conclusionsGossypin exhibited significant neuroprotective effects against CIS-induced neurotoxicity via antioxidant (TNF-α), anti-inflammatory (NF-kB), and anti-apoptotic (BCL2/BAX ratio, nNOS) mechanisms by regulating various key regulatory genes, suggesting that it may be a promising adjuvant therapy to protect against the neurotoxic side effects of cisplatin in cancer treatment.
Indexed as
Identifiers
40261449What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.